SLC5A2 and metabolic syndrome: Dapagliflozin, the SGLT2 inhibitor shown to reduce cardiovascular death in DECLARE-TIMI 58 and DAPA-HF clinical trials [145,147], was able to preserve the depolarized mitochondrial membrane potential, alter mitochondrial morphology related protein levels (Mfn-1, Mfn-2, and Fis-1), maintain cytosolic Ca2+ homeostasis, and significantly improve cellular oxidative damage, protein-thiol oxidation, and ADP/ATP ratio in cardiomyocytes of insulin-resistant rats with metabolic syndrome [174].